MedPath

Effectiveness of Early Insulin Degludec Administration in Combination with Continuous Intravenous Insulin Infusion in the Management of Diabetic Ketoacidosis: A Prospective Multicenter Randomized Controlled Trial

Phase 3
Conditions
Adults (18 or more than 18 years old) with Diabetic ketoacidosis
Basal insulin
Degludec
Diabetic ketoacidosis
Rebound hyperglycemia
Hypoglycemia
Hypokalemia
Type 1 diabetes mellitus
Type 2 diabetes mellitus
Registration Number
TCTR20230408002
Lead Sponsor
Pending
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending (Not yet recruiting)
Sex
All
Target Recruitment
80
Inclusion Criteria

Adult patients who age at least 18 years old and were diagnosed with DKA

Exclusion Criteria

Degludec allergy
Euglycemic DKA
Hemodynamic instability (need vasopressor to maintain hemodynamic status) Pregnant or breastfeeding women

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Time to resolution of DKA When meet the complete criteria of DKA resolution Time to resolution of DKA in medical record
Secondary Outcome Measures
NameTimeMethod
Rebound hyperglycemia at least 12 hours after discontinuation of IV insulin infusion Routinely checked capillary blood glucose (at least 4 times per day: before meal and bedtime) after discontinuation of IV insulin infusion
© Copyright 2025. All Rights Reserved by MedPath